Saturday 17 October 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024. In the quarter to June 2026, revenue grew 32.5%, EPS fell 34.2%, free cash flow fell 68.6% and total debt rose 1.52%, each against the same quarter a year earlier.
25.04
2.60
−9.41%
Follow CBLL
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Piotroski F-Score |
4 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
10.80 | 5.18 | — |
P/S ratio |
9.00 | 4.73 | 2.41 |
Altman Z″-Score (non-manufacturers) |
3.97 | 8.21 | (7.73) |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.42) | (2.33) | — |
P/Operating CF |
(74.38) | (31.00) | (16.49) |
P/B ratio |
5.16 | 1.62 | 0.00 |
Price to Tangible BV |
5.16 | 1.62 | 0.00 |
EV/Sales |
7.43 | 2.05 | 2.50 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(16.22) | (3.84) | (4.61) |
EV/FCF |
(15.64) | (3.67) | (4.47) |
Quick Ratio |
9.08 | 15.80 | 1.97 |
Current Ratio |
9.73 | 16.73 | 2.41 |
Net Debt/EBITDA |
2.38 | 4.58 | 1.20 |
Debt/Assets |
10.12% | 8.68% | 0.00% |
Debt/Equity |
0.13 | 0.10 | 0.00 |
Asset Turnover |
0.42 | 0.46 | 0.00 |
Operating CF/Net income |
0.76 | 0.87 | 0.99 |
Capex/Depreciation |
5.97 | (1.05) | (1.46) |
Interest Coverage |
(30.90) | (19.93) | (14.32) |
| (30.83%) | (102.53%) | 0.00% | |
| (25.36%) | (28.46%) | 0.00% | |
ROIC |
(229.77%) | (151.76%) | 0.00% |
Return on Tangible Assets |
(31.50%) | (19.58%) | (92.25%) |
Average Days of Receivables |
61.69 | 60.67 | 64.20 |
Research and Development Expense of Revenue |
21.49% | 20.72% | 19.89% |
Selling, General and Administrative Expense of Revenue |
131.97% | 126.67% | 130.92% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
13.72% | 8.27% | 5.92% |
Graham Net Nets |
0.18 | 0.59 | (1.05) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(6.70%) | (20.94%) | (25.36%) |
Free Cash Flow Yield |
(5.28%) | (11.85%) | (23.25%) |
Revenue per Share |
2.44 | 5.48 | 8.53 |
Operating CF per Share |
(1.12) | (2.93) | (5.50) |
Capex per Share |
(0.04) | (0.13) | (0.33) |
Free Cash Flow per Share |
(1.16) | (3.07) | (5.83) |
Cash per Share |
4.36 | 16.27 | 6.50 |
Shareholders Equity per Share |
4.25 | 16.00 | (21.16) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
4.25 | 16.00 | (21.16) |
Free Cash Flow |
(42.33) | (36.64) | (30.92) |
Working Capital |
167.53 | 204.28 | 30.36 |
Capital Expenditures |
(1.52) | (1.60) | (1.76) |
Net Current Asset Value |
146.25 | 183.03 | (119.21) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.02 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
(0.13) | 0.66 | 0.77 |
Cash ROIC |
(12.66%) | (9.05%) | 39.77% |
Accounts Receivable Turnover |
6.87 | 6.95 | 0.00 |
Accounts Payable Turnover |
5.42 | 9.27 | 0.00 |
Inventory Turnover |
1.52 | 1.36 | 0.00 |
Average Days of Payables |
96.01 | 47.99 | 37.83 |
Days of Inventory on Hand |
246.56 | 291.24 | 303.29 |
Average Receivables |
12.97 | 9.42 | — |
Average Payables |
1.99 | 0.94 | — |
Average Inventory |
7.11 | 6.40 | — |
Average Assets |
210.61 | 142.17 | — |
Average Common Equity |
173.25 | 39.46 | — |
Columns are period end dates